On Demand Webinar
3D In Vitro Drug Discovery: When and How to Use Tumor Organoids
The translatability of oncology cell lines and models used for preclinical in vitro drug development needs to be improved. 3D in vitro systems show many benefits compared with standard 2D platforms, including more faithfully recapitulating tissue architecture which influences cellular features and drug response.
Among the many 3D in vitro oncology systems available, organoids and primary cell cultures are considered the most clinically relevant as they are directly derived from patient tumor samples, as well as normal tissue.
In this webinar, Dr Rajendra Kumari reviews the main features and differences between available 3D in vitro models. She discusses when to best implement organoids vs standard 3D models at each step of the drug development cascade, with particular emphasis on how organoids are changing traditional approaches to drug screening.
Watch This Webinar to Learn:
- The key differences between 3D in vitro systems, such as cell lines and patient-derived models including organoids
- How to select the right 3D in vitro platform for your drug development program based on model features, benefits, and limitations
- When to use HUB Organoids compared to primary cell cultures or other 3D systems
- Why HUB Organoids are a superior and predictive research system for late stage, as well as early stage, drug development applications
- How PDX-derived organoids (PDXO) expand the repertoire of patient-derived in vitro models available for drug screening
Who Should Watch:
- Drug developers interested in understanding optimal times/applications for introducing tumor organoids into oncology drug development
- Decision makers from biotech and pharmaceutical companies who are looking to enhance the translatability of their early stage drug development programs
- Researchers interested in using cutting edge 3D in vitro platforms such as tumor organoids that recapitulate human tumors in vivo
About The Presenter:
Dr Rajendra Kumari is the Global Head of Scientific Communications for Crown Bioscience, providing scientific guidance and communications on company products, services, and R&D.
Rajendra received her PhD from the University of Leicester in Molecular Pharmacology, following which she joined the lab of Prof. Sue Watson as a postdoctoral fellow in the Division of Pre-clinical Oncology, School of Clinical Sciences, University of Nottingham (UoN). In 2005, Rajendra took the role of Project and Business Manager of the Preclinical Oncology Services (PRECOS) contract research business unit where she built up and managed the portfolio of preclinical in vitro and in vivo projects, products, team and clients, as well as marketing and developing the commercial processes of PRECOS.
Rajendra’s expertise in cancer cell biology and model development helped to build PRECOS, develop an academic career as a lecturer in the School of Clinical Sciences, as well as co-founding the Ex Vivo Pharmacology Centre of Excellence (UoN), which recapitulates the tumor microenvironment through use of clinically-derived tissue. Rajendra was pivotal in the growth of the business unit and commercialization of research which led to the establishment of the spinout of PRECOS Ltd in 2010, acting as Chief Operations Officer, Board Director and co-founder, until merger with CrownBio in July 2013 where she then acted as GM/CSO for CrownBio UK for 4 years.
Rajendra is a member of the American Association of Cancer Research, British Association of Cancer Research, the NC3Rs Cancer Research Advisory Group, and has authored over 40 abstracts and publications.